TLDR
- Servier agreed to acquire Day One Biopharmaceuticals (DAWN) for $21.50 per share in an all-cash deal worth approximately $2.5 billion
- The offer represents a ~68% premium to DAWN’s closing price on Thursday and an 86% premium to its 30-day volume-weighted average price
- DAWN stock surged ~66% in premarket trading following the announcement on March 6, 2026
- Day One’s board unanimously approved the deal and recommended shareholders accept the tender offer
- The transaction is expected to close in Q2 2026, subject to antitrust clearance and majority tender conditions
Day One Biopharmaceuticals (DAWN) has agreed to be acquired by French pharma group Servier in an all-cash deal worth roughly $2.5 billion. The news sent DAWN stock up about 66% in premarket trading on Friday, March 6.
https://x.com/FenwickWest/status/2029944210065969265?s=20
Under the terms of the agreement, Servier will pay $21.50 per share for all outstanding Day One stock. That price is a 68% premium to DAWN’s closing price on Thursday and an 86% premium to its 30-day volume-weighted average price.
Day One Biopharmaceuticals, Inc., DAWN
The deal is not subject to a financing condition, which removes one common obstacle that can derail acquisitions. Closing is expected in Q2 2026, pending U.S. antitrust clearance and a majority tender from DAWN shareholders.
Day One’s board reviewed the terms and voted unanimously to recommend shareholders tender their stock. The company agreed to standard non-solicitation provisions and a break fee of $87.7 million if the deal falls apart under certain conditions.
The announcement didn’t come completely out of nowhere. DAWN stock had already moved higher on Wednesday following reports of takeover speculation, with Jazz Pharmaceuticals (JAZZ) and Ipsen (IPSEY) named at the time as possible suitors.
What Servier Gets
Servier’s main prize is Day One’s lead drug candidate, tovorafenib, which targets low-grade glioma — a type of brain tumor. The treatment has particular relevance in pediatric oncology, an area where Day One has focused most of its pipeline development.
For Servier, the deal extends its rare oncology franchise. The French group, which posted €6.9 billion in revenue for fiscal 2024/25, already invests close to 20% of its branded sales revenue back into R&D. Adding Day One’s assets fits its stated goal of becoming a stronger presence in targeted cancer therapies.
Deal Structure
The transaction is structured as an all-cash tender offer, followed by a second-step merger once conditions are met. The deal does not require Servier to secure new financing, which is seen as a sign of deal certainty.
The $87.7 million break fee provides some downside protection for Day One if the transaction doesn’t close as expected.
Prior to this deal, the most recent analyst price target on DAWN was $17.00 per share with a Buy rating — well below the $21.50 acquisition price.
DAWN’s market cap prior to the announcement stood at approximately $1.35 billion. The $2.5 billion deal value reflects the premium Servier is paying to secure the pipeline.
Day One is headquartered in Brisbane, California. The acquisition, if completed, will hand full ownership to Servier, an independent group based in France with medicines sold in more than 130 countries.
Considering a new stock? You may want to see what’s on our watchlist first.
Our team at Knockout Stocks follows top-performing analysts and market-moving trends to spot potential winners early. We’ve identified five stocks gaining quiet attention that could be worth watching now. Create your free account to unlock the full report and get ongoing stock insights.Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
